A number of amendments to the Eurasian patent regulations concerning inventions and industrial designs have recently been adopted. These amendments will enter into force on 1 February 2026. Additionally, the Eurasian Patent Office (EAPO) will raise its official fees from the same date.
Increase in Eurasian official fees as of 1 February 2026
The forthcoming fee increase will impact all significant procedural actions before the EAPO. This includes the filing of Eurasian applications (from filing through to grant), amendments, term extensions, assignment recordals, and name changes.
For example, the basic official fee for filing a patent application or requesting substantive examination will both increase to 70000 RUB from 60000 RUB. The granting and publication fee will increase to 45000 RUB from 40000 RUB.
In addition, the official fee for requesting a patent term extension will increase to 60000 RUB from 20000 RUB, and the fee for restoring a missed term during prosecution of a Eurasian application will increase to 70000 RUB from 35000 RUB.
If you plan to file a Eurasian patent application or currently have applications pending with the EAPO, it is advisable to pay any outstanding official fees before 1 February 2026. This will help minimize your costs.
Key amendments of the Eurasian patent regulations
The main amendments to the patent regulations affecting Eurasian patent applications can be summarised as follows:
- The maximum period for extending the time limit for replying to an office action will be set at 24 months.
- Prior disclosures contained in published patent documents will not benefit from a grace period. Accordingly, the grace period will apply exclusively to disclosures made in non-patent sources. According to the Eurasian Patent Office (EAPO), this interpretation has already been applied in established practice and will now be expressly codified in the patent regulations.
- Techniques for human cloning and human clones, techniques for modifying the genetic integrity of human embryo cells, as well as the use of human embryos for industrial or commercial purposes, will be expressly excluded from patentability.
- During prosecution of parallel applications within the same patent family, the EAPO may require the applicant to submit search reports issued by other patent offices.
- The subject matter of the claims in respect of which a search has been carried out by the patent office and for which an examination fee has been paid may not be replaced by subject matter that does not, together with the originally searched subject matter, constitute a single general inventive concept in accordance with the requirement of unity of invention. Any such new subject matter may not be introduced into the claims of the pending Eurasian application and may only be pursued in a divisional application. A similar approach has been applied in the EAPO practice since 2022 and will now be explicitly reflected in the patent regulations.
Please feel free to contact our patent attorneys, Erik Viik or Linda Norrgård, if you have any questions.